Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Eli Lilly and Company

The two companies dominate the market for obesity medications. 


Novo Nordisk Pursues Injunction to Block Eli Lilly’s (LLY) Advertisements

The new medication helps people who also have diabetes and cardiovascular disease. 


Eli Lilly (LLY) Targets 2027 for Approval of Its Next-Generation Obesity Drug

In a report released today, from Ord Minnett maintained a Hold rating on CSL, with a price target of A$123.30. In addition to Ord Minnett, CSL also...

Ord Minnett Reaffirms Their Hold Rating on CSL (CMXHF)

SoFi’s ($SOFI) fintech premium will be on trial when the company reports its Q2 results on July 29 before the opening bell. Although the core lendi...

SoFi Stock’s Fintech Premium Is on Trial in Q2

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on Capital One Financial (COF) and Ally Financial (ALLY)...

Analysts Are Bullish on Top Financial Stocks: Capital One Financial (COF), Ally Financial (ALLY)

Analysts have been eager to weigh in on the Financial sector with new ratings on Ally Financial (ALLY), Wintrust Financial (WTFC) and Hancock Whitn...

Analysts’ Opinions Are Mixed on These Financial Stocks: Ally Financial (ALLY), Wintrust Financial (WTFC) and Hancock Whitney (HWC)

In a report released today, Emily Field from Barclays maintained a Buy rating on Eli Lilly & Co, with a price target of $1,400.00. According to Tip...

Barclays Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tyra Bioscience (TYRA), Eli Lilly & Co (LLY) and Per...

Analysts Are Bullish on These Healthcare Stocks: Tyra Bioscience (TYRA), Eli Lilly & Co (LLY)

RBC Capital analyst Craig Wong-Pan maintained a Hold rating on CSL on July 16 and set a price target of A$108.00. The company’s shares closed last ...

RBC Capital Sticks to Their Hold Rating for CSL (CMXHF)

In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Hold rating on Eli Lilly & Co, with a price target of $1,135.00. Acco...

Eli Lilly & Co (LLY) Gets a Hold from Berenberg Bank

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly And Company (LLY) is running a new long‑term safety stu...

Lilly Expands ALS Pipeline With Long‑Term Safety Study for LY4256984

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company is running a Phase 1 trial called “A Phase ...

Lilly Quietly Expands Its Obesity Pipeline With New Early-Stage LY4174794 Trial

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The long term follow up study of AAVAnc80-antiVEGF gene therapy a...

Lilly-Backed Gene Therapy Study Tracks Long Term Safety in Vestibular Schwannoma

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 1 study titled “A Phase 1, Investigator- and Participan...

Eli Lilly Expands Obesity Pipeline With New Phase 1 Eloralintide Trial

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) is running a Phase 1 study called “A ...

Lilly’s Tersolisib Food-Effect Study Moves Forward, Adding Depth to Its Early-Stage Pipeline

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The Phase 1 study A Phase 1 Study to Investigate the Pharmacokine...

Eli Lilly’s New Phase 1 Trial for LY4268989 Signals Fresh Pipeline Momentum

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) has completed a Phase 2 study titled ...

Lilly’s Mazdutide AUD Trial Completion Signals New Optionality in Addiction Treatment

AtaiBeckley N.V. ($ATAI) stock surged on Thursday after the clinical-stage biopharmaceutical company announced an acquisition agreement with global...

Why Is AtaiBeckley N.V. (ATAI) Stock Up Today?

The pharma giant has a history of treating mental health conditions. 


Eli Lilly (LLY) Buys Psychedelic Drug Maker AtaiBeckley for $2.8 Billion

There’s a lot to be optimistic about in the Consumer Cyclical sector as 2 analysts just weighed in on Holley (HLLY) and Dauch Corporation (DCH) wit...

Analysts Are Bullish on Top Consumer Cyclical Stocks: Holley (HLLY), Dauch Corporation (DCH)

Nelly Group AB ( ($SE:NELLY) ) has provided an update. Nelly Group AB reported weaker financial results for the second quarter of 2026, with net re...

Nelly Group Posts Lower Q2 Earnings but Strengthens Cash Position

In a report released today, Laura Sutcliffe from Citi maintained a Hold rating on CSL, with a price target of A$110.00. According to TipRanks, Sutc...

Citi Remains a Hold on CSL (CMXHF)

The pharma giant reports financial results on Aug. 5. 


Eli Lilly Stock (LLY) Gets a Price Target Boost Heading into Earnings

BMO Capital analyst Evan Seigerman maintained a Buy rating on Eli Lilly & Co today and set a price target of $1,300.00. According to TipRanks, Seig...

BMO Capital Sticks to Its Buy Rating for Eli Lilly & Co (LLY)

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on PennyMac Financial (PFSI) and Ally Financial (ALLY) w...

Analysts Offer Insights on Financial Companies: PennyMac Financial (PFSI) and Ally Financial (ALLY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Resmed (RMD) and Eli Lilly & Co (LLY). Resmed (RMD...

Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Eli Lilly & Co (LLY)

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co on July 10 and set a price target of $1,280.00. The company’s shares clo...

Wells Fargo Reaffirms Their Buy Rating on Eli Lilly & Co (LLY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AbbVie (ABBV) and Eli Lilly & Co (LLY) with bullish ...

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Eli Lilly & Co (LLY)

There is more to the company than weight-loss drugs.


Eli Lilly Stock (LLY) Gets a Boost as Eczema Treatment Receives a Positive Recommendation in Canada

Cathie Wood’s ARK Invest made another round of notable portfolio changes on Wednesday, July 8. According to the firm’s daily trade disclosure, Wood...

Cathie Wood Buys More SpaceX, Sells AMD, BioNTech, and Other Growth Stocks, 7/9/26

Eli Lilly’s ($LLY) stock is getting a boost on an otherwise down day for markets on news that its drug to treat the skin condition eczema has been ...

Eli Lilly Stock (LLY) Gets a Boost as Eczema Treatment Is Approved in Canada

There’s a lot to be optimistic about in the Financial sector as 2 analysts just weighed in on TeraWulf Inc (WULF) and Ally Financial (ALLY) with bu...

Analysts Offer Insights on Financial Companies: TeraWulf Inc (WULF) and Ally Financial (ALLY)

The company has several catalysts to drive its share price higher. 


Several Analysts Pounds the Table on Eli Lilly Stock (LLY) Heading into Earnings

Novo Nordisk’s ($NVO) shares rose about 1% during Wednesday’s pre-market session as the U.S. Medicare health insurance program began covering obesi...

Novo Nordisk Stock (NVO) Rises as Medicare Starts Covering Obesity Drugs

UBS analyst David Low maintained a Buy rating on CSL today and set a price target of A$158.00. Low covers the Healthcare sector, focusing on stocks...

UBS Reaffirms Their Buy Rating on CSL (CMXHF)

The shares recently hit an all-time high. 


Eli Lilly Stock (LLY) Retreats as China Threats Emerge

Analysts have been eager to weigh in on the Financial sector with new ratings on Ally Financial (ALLY) and Wintrust Financial (WTFC). Ally Financia...

Analysts Conflicted on These Financial Names: Ally Financial (ALLY) and Wintrust Financial (WTFC)

Macquarie analyst Christine Trinh maintained a Hold rating on CSL today and set a price target of A$114.00. According to TipRanks, Trinh is an anal...

Macquarie Keeps Their Hold Rating on CSL (CMXHF)

Ord Minnett analyst maintained a Hold rating on CSL today and set a price target of A$117.00. In a report released today, Citi also maintained a Ho...

CSL (CMXHF) Receives a Hold from Ord Minnett

The company is spending $27 billion to build four new plants. 


FDA to Expedite Review of Eli Lilly’s (LLY) New Manufacturing Facilities

Stocks ended the week lower as investors pulled back from risk assets and rotated into safer parts of the market. The Dow Jones Industrial Average ...

The Week That Was, The Week Ahead: Macro and Markets, June 28

Eli Lilly & Co ( ($LLY) ) has risen by 9.62%. Read on to learn why. Eli Lilly & Co shares climbed 9.62% over the past week as investors cheered


Eli Lilly & Co Soars on Drug Pipeline Breakthroughs

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) is running a Phase 3 study called “A ...

Eli Lilly Expands Donanemab Alzheimer’s Trial Into China, Targeting Preclinical Patients

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The study “An Annual Dosing Study of Donanemab in Participants Wh...

Eli Lilly Tests Annual Donanemab Dosing: What Ongoing Alzheimer’s Study NCT07602582 Means for Investors

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly and Company (LLY) has updated a Phase 1b trial titled “...

Lilly Ends Early-Stage Prostate Cancer Combo Trial, Nudging Investor Focus Back to Core Oncology Assets

The company has a diverse portfolio of medications. 


Here’s Why Eli Lilly Stock (LLY) Is Up 6% Today

WSW, NY, June 25th, 2026, FinanceWire A May 2026 Big Pharma acquisition just validated the surgical site infection prevention market at the highest...

Lilly’s $780M Bet is Reshaping Surgical Infection Prevention, and PolyPid’s Asset is Hiding in Plain Sight

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Eli Lilly & Co. (LLY) has launched a Phase 3 study titled “A Phas...

Lilly Targets Youth Diabetes With New Oral GLP-1 Trial, Expanding Its GLP-1 Footprint

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. The phase 1 study “A Single-Ascending and Repeated Subcutaneous D...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LLY	$1,194.80	+0.75%	644.58K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LLY	$1,194.80	+0.8%	644.58K
3
4
5
6

LLY

LLY

Get Eli Lilly and Company Data in Excel

Get Eli Lilly and Company Data in Excel